Back to search
Breast Cancer, HR+/HER2- Early-Stage
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Breast Cancer, HR+/HER2- Early-Stage trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which Breast Cancer, HR+/HER2- Early-Stage trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting wor…
The goal of this performance study is to learn if treatment with neoadjuvant endocrine therapy compared to chemotherapy has comparable efficacy, but better qual…
This is a national clinical trial (Spain), conducted in approximately 5 sites, where patients who agree to participate will be included in one of two exercise p…
The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standa…
* This is a Phase II, multicenter, randomized clinical trial evaluating a ctDNA-guided approach to de-escalate adjuvant chemotherapy in patients with hormone re…
For patients with breast cancer, it's important to find any remaining cancer cells after they've had their main treatment. Even a few cells, called minimal resi…
The purpose of this study is to find out how often the researchers can avoid an ALND in patients with early-stage, node-positive HR+/HER2- breast cancer who are…
The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) versus aromatase inhibitors (…